LY2228820

• CAT Number: I005171
• CAS Number: 862507-23-1
• Molecular Formula: C₂₆H₃₇FN₆O₆S₂
• Molecular Weight: 612.74
• Purity: ≥95%
• Target: p38
• Solubility: DMSO:38mg/mL
• Storage: 3 years -20C powder
• IC50: 7/3 nM(p38α/p38β MAPK) [1]
• InChI: InChI=1S/C24H29FN6.2CH4O3S/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6;2*1-5(2,3)4/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30);2*1H3,(H,2,3,4)
• InChIKey: NARMJPIBAXVUIE-UHFFFAOYSA-N
• SMILES: CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O

LY2228820 (Cat.No:I005171) is a small molecule compound that acts as a potent and selective inhibitor of the transforming growth factor-beta type I receptor kinase (TGF-βRI). It has been studied for its potential therapeutic applications in various diseases, including cancer and fibrosis. By inhibiting TGF-βRI, LY2228820 interferes with the TGF-β signaling pathway, which plays a critical role in cell growth, differentiation, and immune regulation.

Reference

[1]. Mader M, et al. Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties. Bioorg Med Chem Lett, 2008, 18(1), 179-183.
[2]. Ishitsuka K, et al. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol, 2008, 141(5), 598-606.